Acinetobacter News and Research

RSS
Tru-D UV-C device effective in reducing pathogens on all environmental surfaces in hospital patient rooms

Tru-D UV-C device effective in reducing pathogens on all environmental surfaces in hospital patient rooms

Stratatech receives SBIR grant to develop anti-infective living human skin substitute

Stratatech receives SBIR grant to develop anti-infective living human skin substitute

NIAID announces four new contracts for clinical trials to address problem of antimicrobial resistance

NIAID announces four new contracts for clinical trials to address problem of antimicrobial resistance

NIH awards two new grants to develop Avidocin platform

NIH awards two new grants to develop Avidocin platform

NC State receives $1.8M defense grant to test molecule efficacy against antibiotic-resistant infections

NC State receives $1.8M defense grant to test molecule efficacy against antibiotic-resistant infections

Tetraphase Pharmaceuticals presents preclinical data of TP-434 antibacterial drug

Tetraphase Pharmaceuticals presents preclinical data of TP-434 antibacterial drug

New antibacterial peptide effective against infections in burn or blast wounds

New antibacterial peptide effective against infections in burn or blast wounds

Scientists report frog skin contains new genera of antibiotics

Scientists report frog skin contains new genera of antibiotics

Scientists to develop new antibiotics to tackle infection-causing bacteria

Scientists to develop new antibiotics to tackle infection-causing bacteria

Advanced Life Sciences enters agreement with UBC to develop antimicrobial peptides

Advanced Life Sciences enters agreement with UBC to develop antimicrobial peptides

Cubist Pharmaceuticals total net revenues for second-quarter 2010 increase 29%

Cubist Pharmaceuticals total net revenues for second-quarter 2010 increase 29%

Aggressive infection control measures stop spread of Acinetobacter baumannii at Dallas hospital

Aggressive infection control measures stop spread of Acinetobacter baumannii at Dallas hospital

Cubist commences enrollment in Phase 2 study of CXA-201 for complicated intra-abdominal infections

Cubist commences enrollment in Phase 2 study of CXA-201 for complicated intra-abdominal infections

Cubist Phase 2 trial for efficacy of CXA-101 in complicated urinary tract infections meets objectives

Cubist Phase 2 trial for efficacy of CXA-101 in complicated urinary tract infections meets objectives

Automated UV radiation helps decontaminate healthcare-associated pathogens

Automated UV radiation helps decontaminate healthcare-associated pathogens

Effective compound against antibiotic-resistant biofilms

Effective compound against antibiotic-resistant biofilms

Accelr8 Technology to present results of culture-free, quantitative pathogen identification study at 110th ASM

Accelr8 Technology to present results of culture-free, quantitative pathogen identification study at 110th ASM

Oculus Innovative Sciences introduces Microcyn Solution for treatment of post-surgical wounds

Oculus Innovative Sciences introduces Microcyn Solution for treatment of post-surgical wounds

Kenta Biotech and Rentschler Biotechnologie sign agreement to develop antibody against MRSA

Kenta Biotech and Rentschler Biotechnologie sign agreement to develop antibody against MRSA

Growing public health threat from surge in drug-resistant strains of acinetobacter

Growing public health threat from surge in drug-resistant strains of acinetobacter